ChromaDex (NASDAQ:CDXC) Price Target Raised to $8.10 at LADENBURG THALM/SH SH

ChromaDex (NASDAQ:CDXC) had its target price hoisted by equities research analysts at LADENBURG THALM/SH SH from $6.80 to $8.10 in a research note issued on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. LADENBURG THALM/SH SH’s target price would indicate a potential downside of 5.26% from the company’s current price.

CDXC has been the subject of several other research reports. Roth Mkm raised their price objective on ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. StockNews.com upgraded ChromaDex from a “buy” rating to a “strong-buy” rating in a research note on Monday, February 24th.

ChromaDex Stock Up 52.7 %

CDXC traded up $2.95 during trading hours on Wednesday, hitting $8.55. 18,667,777 shares of the company’s stock were exchanged, compared to its average volume of 822,043. The stock has a market cap of $653.07 million, a price-to-earnings ratio of 855.86 and a beta of 2.21. ChromaDex has a 1-year low of $1.57 and a 1-year high of $9.18. The stock’s 50-day moving average is $5.62 and its two-hundred day moving average is $5.11.

Insider Activity at ChromaDex

In other ChromaDex news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the company’s stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $6.19, for a total value of $230,026.59. Following the sale, the director now owns 244,179 shares in the company, valued at $1,511,468.01. This represents a 13.21 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 9.64% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On ChromaDex

Large investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC boosted its stake in ChromaDex by 0.5% in the 4th quarter. Geode Capital Management LLC now owns 1,154,778 shares of the company’s stock valued at $6,128,000 after purchasing an additional 5,186 shares during the period. D. E. Shaw & Co. Inc. grew its position in shares of ChromaDex by 1,785.9% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,011,290 shares of the company’s stock worth $5,365,000 after purchasing an additional 957,665 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of ChromaDex by 68.0% during the fourth quarter. Renaissance Technologies LLC now owns 712,788 shares of the company’s stock worth $3,781,000 after purchasing an additional 288,588 shares during the period. Arrowstreet Capital Limited Partnership raised its position in shares of ChromaDex by 288.1% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 662,956 shares of the company’s stock valued at $3,517,000 after buying an additional 492,148 shares in the last quarter. Finally, State Street Corp boosted its stake in shares of ChromaDex by 11.3% in the third quarter. State Street Corp now owns 618,028 shares of the company’s stock valued at $2,256,000 after buying an additional 62,692 shares during the period. Institutional investors own 15.41% of the company’s stock.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.